Research Studies: Bipolar Disorder
DBSA does not endorse nor recommend any particular research study. Patients should discuss all options with their health care providers and family members before beginning any study.
Many people think that participating in a research study means they will get better treatment for their illness. While this may be true, it's important to remember that a research study is conducted for research purposes—it does not ensure better or safer treatment.
Taking part in a study does not guarantee individual benefits to the participant in the form of newer or safer treatment. The contribution made participating in a research study is to science first and to the patient second.
DBSA, its advisors, and consultants do not endorse or recommend the use of any specific treatment or medication. For advice about specific treatment or medication, patients should consult their physicians and/or mental health professionals.
Dynamic Inflammatory and Mood Predictors of Cognitive Aging in Bipolar Disorder (San Diego/La Jolla, CA)
UCSD Department of Psychiatry is conducting research on how short-term changes in inflammatory markers (signs of healing response) and emotion contribute to long-term changes in thinking in bipolar disorder.
The study includes:
Compensation is up to $165 for approximately 10 hours per year, spread out over 3 separate visits in a 2-week period. The study lasts for four years. The primary location is in La Jolla, but home visits and transportation may be available.
Deadline for Enrollment: April 2020
Neural mechanisms of perception across the schizo-bipolar spectrum (Newark, NJ)
As part of this study, participants will be asked questions regarding their clinical/psychiatric history. In a separate session, participants will enter an fMRI scanner and perform behavioral tasks while looking at a screen. Participants will be compensated $20-$30 per hour for each session. Total compensation for completing the study could be $90-$200.
Deadline for Enrollment: 3/31/2020
RGH-MD-53 (Lauderhill, FL)
A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter, fixed-dose clinical trial evaluating the efficacy, safety and tolerability of Cariprazine in patients with Bipolar I Depression. Participants must wash out of current psychiatric medications; cannot initiate or terminate psychotherapy, but can maintain current psychotherapy as long as it has been consistent for 3 months. The chances of receiving a placebo are 1 out of 3 or 33%. The placebo period will last 7 weeks.
Deadline for Enrollment: 03/31/2018
ITI-007-402 (Lauderhill, FL)
A phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ITI-007 adjunctive to Lithium or Valproate in the treatment of patients with major depressive episodes associated with Bipolar I or II Disorder (Bipolar Depression). During the study time frame, no additional psychiatric medications are allowed and no structured psychotherapy is allowed. The chances of receiving a placebo are 1 out of 3 or 33%. The placebo period will last 8 weeks.
Deadline for Enrollment: 11/30/17
RGH-MD-53 (Charleston, South Carolina)
A phase 3, randomized, double-blind, placebo controlled, parallel-group multicenter, fixed-dose clinical trial evaluating the efficacy, safety and tolerability of Cariprazine in patients with Bipolar I Depression. Participants must wash out of current psychiatric medications; cannot initiate or terminate psychotherapy, but can maintain current psychotherapy as long as it has been consistent for 3 months. The chances of receiving a placebo are 1 out of 3 or 33%. The placebo period will last 7 weeks.
Deadline for Enrollment: March 31, 2018
ITI-007-401 (North Miami, FL)
A phase 3 randomized, double-blind, placebo-controlled, multi-center study to asses the efficacy and safety of ITI-001 monotherapy in the treatment of patients with major depressive episodes associated with bipolar I or II disorder (bipolar depression). During the study time frame, no additional psychiatric medications are allowed and no structured psychotherapy is allowed. The chances of receiving a placebo are 1 out of 3 or 33%. The placebo period will last 8 weeks.
Deadline for Enrollment: November 31, 2017
N-acetylcysteine in the treatment of depressive symptoms in youth at high-risk for bipolar disorder: a functional connectivity study (Cincinnati, Ohio)
Researchers at the Department of Psychiatry of the University of Cincinnati are conducting a research study looking at the effects of a dietary supplement (N-Acetylcysteine) on mood symptoms and brain functioning in adolescents and young adults at familial risk for bipolar disorder who are feeling depressed.
Deadline for Enrollment: 6.28.2017
Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorder (Miami , Florida)
The University of Miami, Miller School of Medicine Department of Psychiatry and Behavioral is conducting a 14-week research study to see if two nutritional over-the-counter supplements help improve mood and reduce alcohol consumption in individuals diagnosed with Bipolar Disorder and Alcohol Use Disorder. Participation is confidential.
Deadline for Enrollment: January 2020
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
The goal of this study is to test the use of a mobile application that can help individuals track changes in their mood using their smartphones. Participants will download the Cogito Companion mobile app onto their smartphone. This app will passively monitor participants' behavior through GPS, call frequency, and SMS count, but will never store the contents of calls or texts. Participants will also have the option to leave brief "audio diaries" in the app, or private voice recordings about how their day is going, and will receive real-time feedback on their mood from these recordings. The content of these recordings will not be stored. The app will also administer optional monthly and weekly questionnaires about participant health and well being. The app will remain on participants' phones for six months. At the end of six months, the app will be removed from their phones and all data will be deleted. https://moodnetwork.org/members/study-opportunities
Deadline for Enrollment: June 30, 2017
Reward Processing in Unipolar and Bipolar Depression
Researchers at McLean Hospital are currently recruiting individuals who are experiencing symptoms of depression or bipolar disorder, for an exciting new study that uses brain imaging to identify the ways different people will respond to reward, and how this relates to disturbances in circadian rhythms.
We are seeking right-handed individuals, 18-45 years old, with no serious medical or neurological illness other than depression or bipolar disorder.
This study consists of 2 sessions that each last between 1-3.5 hours. During these sessions participants will receive brain scans using MRI (a non-invasive brain imaging technique), and will also receive a comprehensive clinical assessment from a trained clinical interviewer. If eligible to participate, individuals can earn up to $245.80.
If you are interested in participating, please complete our online screening survey at www.mcleanstudy.org.
Deadline for Enrollment: August 2017
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression (Hoffman Estates, IL)
You may be eligible to participate in this study if you are between 18-65 years old, have been diagnosed with Bipolar I Depression, are currently suffering a major depressive episode that has lasted more than 4 weeks but not longer than 12 months. This study lasts approximately 9 weeks, including a screening period of up to 14 days, followed by a 6 week treatment period and 1 week safety follow-up period.
Exclusion criteria includes prior participation with any clinical trials, involving experimental or investigational drugs, within 6 months. Initiation or termination of psychotherapy for depression within the 3 months. Treatment period is 6 weeks where participants will be randomized to receive either 1.5mg , 3.0mg of study drug or placebo.
Stanford Daily REST Study (San Francisco Bay Area)
The Department of Psychiatry at Stanford University is recruiting 14-21 year old youth who have bipolar disorder to participate in a PAID research study on sleep and mood patterns.
Sleep is commonly disrupted in adults who are diagnosed with bipolar disorder. However, there has been limited investigation of sleep in youth bipolar disorder. Our aim is to better understand sleep in youth diagnosed with bipolar disorder, and to explore the relation of sleep to mood in this population. The goal of this work is to help advance new treatments for youth affected with bipolar disorder.
The study has 3 parts:
You will receive $215 for completing the study.
Deadline for Enrollment: 4/1/2018
Genetic Assessment of Positive Traits in the Bipolar and Schizophrenia Spectra (La Jolla, CA)
UCSD Department of Psychiatry needs your help with their investigation of positive traits associated with bipolar spectrum disorders.
PAYMENT IS $15/HOUR, PLUS $10 FOR DNA
Testing may last 4 to 8 hours.
Participants Must Be:
Your Participation Will Entail:
Please call (858) 246-1888 or email firstname.lastname@example.org for more information.
Deadline for Enrollment: Ongoing
Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder (Columbus, Ohio)
The purpose of this research study is to compare the effects of the study drug, ziprasidone, with a placebo to find out which is better for treating manic episodes in children with Bipolar I Disorder. Ziprasidone is approved in the US for the treatment of acute mania and mixed states associated with bipolar disorder in adults.
Mood stabilizers and antipsychotics are not allowed during the study. Participants have 1 in 2 chance of receiving placebo for 6 weeks. Paid post study care will be available to all study participants at the end of their participation in the study.
Deadline for Enrollment: January 2018
Bipolar and Schizophrenia Network for Intermediate Phenotypes (Chicago, IL)
The overall goal of this study is to test for biological traits of psychosis that may be related to disorders ranging from schizophrenia to bipolar disorder. In addition, we wish to examine whether these biological traits may be genetically inherited.
People ages 18-60 diagnosed with at least one of the following:
Participants will undergo clinical interview, cognitive testing, self-report questionnaires, one-time blood-draw to study DNA, EEG, Eye Tracking Movement recording and fMRI testing.You will receive a confidential, no-cost, evaluation to see if you qualify to enter. If eligible, you will receive a full clinical assessment at no cost. Compensation: Up to a maximum of $360.00 which includes $10 per visit travel reimbursement.
Deadline for Enrollment: 2/12/2020
Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging (New York/NY)
The study is trying to understand what causes bipolar disorder and how medications treat bipolar depression. If you participate, you will have two different brain scans (an MRI and a PET scan) and antidepressant treatment for free. We will then be able to see whether information on the brain scans connects with how people do on the medications. The medications are common, and are not experimental. You will be able to discuss the treatment with Dr. Lan before starting the study to make sure that it is the proper treatment for you. The medications include valproate (Depakote) and either fluoxetine (Prozac) or citalopram (Celexa). The study is funded by the National Institute of Health (NIH). You will receive $400 in compensation when you complete the brain scans and will be offered up to six months of free appointments with a Columbia psychiatrist.
Deadline for Enrollment: 9/30/2019
A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC-34712) in Adolescents with Schizophrenia or Other Related Psychiatric Disorders (Baltimore, MD)
This research study is being conducted by Kennedy Krieger Institute/centers across the United States to determine whether brexpiprazole is safe and effective in adolescents with schizophrenia or a related psychiatric disorder.
If eligible, the participant will visit the Kennedy Krieger Institute up to 9 times over a period of 102 days. Each visit will take between 30 minutes and 2 hours and will include psychological and behavioral testing, medical history, physical examination, blood draws, HIV testing, vital sign, ECG, urine drug screen, and pregnancy testing for females.
For each completed visit, participants will receive a reimbursement of $75.00 for their time and travel expenses. Please ask a study team member for specifics. All testing is done free of charge.
Please call 443-923-3850 for questions about specific co-ocurring treatments.
Rapid Antidepressant Effects of Ketamine in Bipolar Disorder (Bethesda, MD)
Bipolar disorder and major depressive disorder (MDD) are common, severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses. Recent preclinical and clinical studies suggest that the glutamatergic system is involved in the mechanism of action of antidepressants. In two separate trials, we tested riluzole (an inhibitor of glutamate release) and found it to have antidepressant properties in patients with MDD and bipolar depression (BD). In another study (Substudy 1), we found that the non-competitive NMDA antagonist (ketamine) was effective in treatment-resistant MDD. Ketamine resulted in rapid, robust and relatively sustained antidepressant effects. Response with ketamine occurred within 2 hours and last approximately 1 week. The current protocol consists of 6 subs tudies designed to address 6 major questions. Two of these studies (1 and 5) have met their enrollment quota and sufficient analyzable data has been obtained
Standard antidepressant medications can take weeks or months to achieve their full effects. Several studies seek to better understand the causes of depression and evaluate the mechanisms in the brain that are related to rapid antidepressant improvement. NIH studies enrolls depressed persons between the ages of 18 and 65 (or those with bipolar disorder who are currently in a depressive phase) for an inpatient period of 2- to 3-months. Researchers will evaluate how the experimental medication ketamine, versus placebo, affects glutamate in the brain and whether a rapid reduction of antidepressant symptoms (within hours) can be achieved and sustained.
The studies are conducted at the NIH Clinical Center in Bethesda, Maryland. There is no cost to participate. We enroll eligible participants locally and from around the country. Travel arrangements provided and costs covered by NIMH. (Arrangements vary by distance and by specific study.) After completing the study participants receive short-term follow-up care while transitioning back to a provider.
Participants who consent will have a multimodal MRI and MEG scan in the drug-free period before receiving the intravenous infusion of either ketamine or saline solution. They will repeat the MEG procedure 4-5 hours after each of the two infusions, and will repeat the MRI procedure between the day of infusion to two days following the infusion.
Participants who show an antidepressant response (50% reduction in MADRS) following infusion 1 or infusion 2 will undergo an interim assessment using the same MRI and MEG scan battery to assess relapse (if the response is lost) or sustained response (if the response is retained) 10 to 11 days post-infusion, depending on availability of scanning resources. Non-responders will undergo the interim MRI and MEG scan sessions at 10 to 11 days post-infusion as scan-time allows.
In a subset of 26 participants, total sleep deprivation (TSD) for 40 hours (7am to 11pm the subsequent day) will be investigated at the behavioral and neural level as a rapid acting antidepressant prior to Phase II of this study. Individuals who participate in this optional component of the subs study will require an additional 7 days for their drug free period. In the evening prior to the sleep deprivation period, participants will undergo a baseline 3T MRI (within 2 days of TSD) and a high field 7T MRI scan (within 2 days of TSD) to acquire images of the brain prior to sleep deprivation. This will be followed by one 7T scan after the sleep deprivation period toward the end of the 40 hour period, but before recovery sleep. During the MRI scan participants will play a simple reward-learning task and also perform a cognitive emotional task whereby emotional faces will be presented, while functional images are acquired. Additionally, two MEG scans and two sleep EEGs will be acquired to examine the electrophysiology of response and relapse. During the MEG scan participants will wear an MEG compatible EEG cap and leads. Total sleep deprivation will occur approximately 1 week following the beginning of the drug-free period.
Inclusion criteria for participants with MDD or BD
Exclusion criteria for participants with MDD or BD
Inclusion criteria for control subjects
Exclusion criteria for control subjects
A Clinical Trial of Mobile Telephone based Assessment and Intervention for Persons with Bipolar Disorder or Schizophrenia (La Jolla (San Diego), CA)
The purpose of this study is to evaluate the effectiveness of a mobile real-time cognitive behavioral intervention for serious mental illness (SMI) and to identify the facilitators, barriers, and costs of implementation. We would like to determine whether the addition of a mobile phone monitoring software program to a brief behavioral intervention for bipolar disorder or schizophrenia improves symptoms arising from the disorders. We aim to address symptoms, improve socialization, medication adherence, and relapse prevention.
Participants cannot receive any cognitive behavior therapy while in the study. There are three different groups. One is treatment as usual, one is active control, and one is treatment. There is an equal change of being randomized in each group.
Deadline for Enrollment: 05/31/2017
NIH Research Studies: Bipolar Disorder & Severe Irritability Symptoms (Bethesda, Maryland)
How do the brain and the symptoms change as children grow up?
Participants must have a bipolar diagnosis, or have symptoms of severe irritability. Irritability symptoms include: difficulty handling frustration (severe temper tantrums and rages) and "hyper" behavior (distractible, hyperactive, trouble sleeping).
Call for more information and eligibility criteria.
Deadline for Enrollment: Ongoing
Developing Brain Function in Adolescent (Chicago, IL)
Developing Brain Function in Adolescent Bipolar Disorder
This study focuses on the developmental changes in cognitive and affective neural circuitry functioning in adolescents with Pediatric Bipolar Disorder (PBD) over a three-year period. We will characterize the course of illness and associated neurocognitive function in patients with PBD as well as determine the association between brain function and behavior.
During the study, participants will complete a baseline diagnostic interview, clinical assessments, neurocognitive and neuropsychological tests, and a functional MRI brain scan. Participants will also have the option to draw blood for pharmacogenetic analyses. Testing will be repeated once a year for three years after the baseline visit, four visits total.
Deadline for Enrollment: Ongoing
info, training, events
- Bipolar Disorder
- Screening Center
- Co-occurring Illnesses/Disorders
- Related Concerns
- Brochures (printable)
- eUpdate Newsletter
- Living Successfully Course
- Ask the Doc
- Outside Resources
- DBSA Core Peer Specialist Training
- DBSA Veteran Peer Specialist Training
- Peer Specialist Continuing Education
- Training and Consultation Services
- Mental Health First Aid Training
- Support Group Facilitator Training
- Wellness Options
treatment, tools, research
- Peer Support
peer groups, inspiration
- Help Others
family, friends, peers
How to Help in a Crisis
Help with Symptoms & Treatment
Help with Relationships
Support for Helpers
Balanced Mind Parent Network
- About DBSA
who we are
- Media Kit Facts about Mood Disorders DBSA News Releases & Announcements Public Service Announcements Partnering with DBSA